172 related articles for article (PubMed ID: 24699042)
1. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.
Pan J; Wu C; Xue Y; Qiu H; Chen S; Zhang J; Bai S; Wu Y; Wang Y; Shen J; Gong Y
Cancer Genet; 2014 Mar; 207(3):51-6. PubMed ID: 24699042
[TBL] [Abstract][Full Text] [Related]
2. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular cytogenetic studies in ten patients with hematological malignancies characterized by t(20;21)(q11;q11) resulted from del(20q).
Wu C; Zhang J; Bai S; Yao J; Qiu H; Xue Y; Chen S; Wu Y; Shen J; Pan J
Cancer Genet; 2016 Oct; 209(10):456-462. PubMed ID: 27810074
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
6. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of del(20q) in patients with hematological malignancies.
Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders.
Campbell LJ; Garson OM
Leukemia; 1994 Jan; 8(1):67-71. PubMed ID: 8289501
[TBL] [Abstract][Full Text] [Related]
10. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
11. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and cytogenetic features of 29 cases of myelodysplastic syndrome associated with del(20q)].
Qin S; Liu SH; Bo LJ; Liu XP; Li CW; Dai Y; He GS; Shao ZH
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):171-2. PubMed ID: 15079804
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and cytogenetic study of 6 cases of hematological disorders associated with 20q- and t (20;21) (q11;q11) abnormalities].
Wu CX; Pan JL; Qiu HY; Xue YQ; Chen SN; Zhang J; Wu YF; Shen J; Bai SX; Wang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):138-42. PubMed ID: 23568721
[TBL] [Abstract][Full Text] [Related]
15. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
16. Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes.
Saunders K; Czepulkowski B; Sivalingam R; Hayes JP; Aldouri M; Sekhar M; Cummins M; Ho A; Mufti GJ
Cancer Genet Cytogenet; 2005 Jan; 156(2):154-7. PubMed ID: 15642396
[TBL] [Abstract][Full Text] [Related]
17. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
[TBL] [Abstract][Full Text] [Related]
18. Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
Courville EL; Singh C; Yohe S; Linden MA; Naemi K; Berger M; Ustun C; McKenna RW; Dolan M
Am J Clin Pathol; 2016 Apr; 145(4):459-66. PubMed ID: 27124938
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-).
Li T; Xue Y; Wu Y; Pan J
Br J Haematol; 2004 May; 125(3):337-42. PubMed ID: 15086414
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
Pitchford CW; Hettinga AC; Reichard KK
Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
